BeyondSpring is a biopharmaceutical company headquartered in New Jersey, committed to developing first-in-class treatments for cancer patients. Their lead asset, plinabulin, is a selective immunomodulating microtubule-binding agent being developed for various cancer indications. They also have a subsidiary, SEED Therapeutics, focusing on developing novel 'molecular glues' for breakthrough therapeutics in the Targeted Protein Degradation (TPD) space.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

COM:BEYONDSPRINGPHARMA

BeyondSpring

Last Close

2.07

26/07 20:00

Market Cap

91.48M

Beta: -

Volume Today

13.10K

Avg: -

market

industry

website

crunchbase

ipo date

peer of

Metrics